Archives

  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2025-09
  • 2025-03
  • 2025-02
  • 2025-01
  • 2024-12
  • 2024-11
  • 2024-10
  • 2024-09
  • 2024-08
  • 2024-07
  • 2024-06
  • 2024-05
  • 2024-04
  • 2024-03
  • 2024-02
  • 2024-01
  • 2023-12
  • 2023-11
  • 2023-10
  • 2023-09
  • 2023-08
  • 2023-07
  • 2023-06
  • 2023-05
  • 2023-04
  • 2023-03
  • 2023-02
  • 2023-01
  • 2022-12
  • 2022-11
  • 2022-10
  • 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2022-03
  • 2022-02
  • 2022-01
  • 2021-12
  • 2021-11
  • 2021-10
  • 2021-09
  • 2021-08
  • 2021-07
  • 2021-06
  • 2021-05
  • 2021-04
  • 2021-03
  • 2021-02
  • 2021-01
  • 2020-12
  • 2020-11
  • 2020-10
  • 2020-09
  • 2020-08
  • 2020-07
  • 2020-06
  • 2020-05
  • 2020-04
  • 2020-03
  • 2020-02
  • 2020-01
  • 2019-12
  • 2019-11
  • 2019-10
  • 2019-09
  • 2019-08
  • 2019-07
  • 2019-06
  • 2019-05
  • 2019-04
  • 2018-07

    • TEAD Family in HCC: Prognostic Significance and Ferroptosis

    2026-05-06

    Integrative Analysis Reveals TEAD Family as Prognostic and Ferroptosis Regulators in Hepatocellular Carcinoma

    Study Background and Research Question

    Hepatocellular carcinoma (HCC) represents approximately 90% of primary liver cancers, a disease with rising global incidence and significant mortality due to late-stage diagnosis and limited therapeutic options (Ren et al., 2022). Molecular heterogeneity underlies HCC's pathogenesis, prompting efforts to identify actionable targets for diagnosis, prognosis, and therapy. The transcriptional enhanced associate domain (TEAD) family—composed of TEAD1, TEAD2, TEAD3, and TEAD4—functions as downstream nuclear effectors of the Hippo pathway, a critical regulator of organ size, cell proliferation, and tumorigenesis. While TEAD proteins are established contributors to several solid tumors, their precise biological functions in HCC, particularly regarding cell death mechanisms like ferroptosis, remained unclear prior to this study.

    Key Innovation from the Reference Study

    The referenced work by Ren et al. provides a rigorous integrative analysis combining large-scale bioinformatics with in vitro experimental validation to interrogate TEAD family expression and function in HCC (Ren et al., 2022). Notably, the study identifies TEAD2 and TEAD4 as consistently upregulated in HCC tissues versus normal liver, and demonstrates that TEAD2 downregulation promotes ferroptosis—a form of iron-dependent regulated cell death—via iron accumulation and oxidative damage. This positions the TEAD family, especially TEAD2, as both prognostic biomarkers and functional mediators of ferroptosis in HCC.

    Methods and Experimental Design Insights

    Ren et al. integrated multiple bioinformatics platforms—UALCAN, Oncomine, GEPIA, Kaplan-Meier plotter, WebGestalt, cBioPortal, and TIMER2.0—to systematically assess TEAD family gene expression, prognostic impact, coexpression networks, and immune infiltration correlations in HCC. Experimental validation included knockdown of TEAD2 in HCC cell lines, with subsequent assays for iron accumulation, oxidative stress, and cell viability to directly test ferroptosis induction. Functional enrichment analyses (Gene Ontology, KEGG) and protein-protein interaction (PPI) network mapping further characterized the pathways associated with TEAD dysregulation.

    Protocol Parameters

    • TEAD2 knockdown | siRNA transfection, 48-72 h | HCC cell lines | To assess gene-specific effects on cell death pathways | paper
    • Ferroptosis assay | Iron probe fluorescence, lipid ROS measurement | HCC cell lines post-TEAD2 knockdown | To confirm ferroptotic cell death phenotype | paper
    • Expression analysis | RT-qPCR, Western blot | Tumor vs. normal tissues | To quantify TEAD family member abundance | paper
    • Workflow adaptation | Use of RIP1 kinase inhibitors in necroptosis or ferroptosis cross-talk studies | HCC or other cancer models | To dissect cell death modality specificity | workflow_recommendation

    Core Findings and Why They Matter

    The study's central results reveal that TEAD2 and TEAD4 are markedly overexpressed in HCC compared to adjacent normal liver tissue. High TEAD2 expression correlates with poorer disease-specific, overall, progression-free, and relapse-free survival, as established through Kaplan-Meier analyses (Ren et al., 2022). Functional knockdown of TEAD2 leads to increased iron accumulation and lipid peroxidation, signature events of ferroptosis, resulting in a significant reduction of HCC cell viability. These findings suggest that the TEAD family, as effectors of the Hippo pathway, not only serve as markers for aggressive HCC but also regulate vulnerability to ferroptosis—a cell death pathway increasingly recognized as a therapeutic target in cancer. Additionally, TEAD family expression was linked to the degree of immune cell infiltration, including macrophages, neutrophils, dendritic cells, and T/B lymphocytes, implicating TEADs in modulating the tumor immune microenvironment.

    Comparison with Existing Internal Articles

    Recent advances in programmed cell death research highlight the importance of dissecting distinct modalities such as necroptosis and ferroptosis in disease models. For example, the article "Taraxasterol Suppresses Necroptosis to Restore BMSC Balance in Osteoporosis" demonstrates how modulation of cell death pathways can influence disease phenotypes outside of oncology, specifically in bone metabolism. Similarly, "Necrostatin-1: Selective RIP1 Kinase Inhibitor for Necroptosis Research" and APExBIO's Necrostatin-1 review establish the value of chemical probes like Necrostatin-1 for dissecting necroptosis in acute kidney injury and liver inflammation. While these internal resources focus on necroptosis and its pharmacological inhibition—particularly using RIP1 kinase inhibitors such as Necrostatin-1—the present TEAD/HCC study expands the landscape by focusing on ferroptosis and transcriptional regulation, providing a complementary perspective on cell death control in cancer. Together, this body of research enables researchers to differentiate and manipulate distinct cell death pathways in various disease contexts.

    Limitations and Transferability

    Although the integrative approach and experimental validation in this study are robust, several limitations merit consideration. The functional in vitro experiments were limited to cell line models, which may not fully recapitulate the complexity of in vivo tumor microenvironments or immune interactions (Ren et al., 2022). The mechanistic link between TEAD-regulated transcription and ferroptosis remains to be fully elucidated at a molecular signaling level. Additionally, while immunological correlations are intriguing, direct causative experiments dissecting TEAD's role in immune modulation in HCC are warranted. Consequently, while these findings offer valuable new biomarkers and potential targets, further in vivo and clinical studies are needed to confirm translational relevance.

    Research Support Resources

    For researchers investigating regulated cell death mechanisms in cancer, especially the interplay between necroptosis and ferroptosis, chemical probes remain essential tools. Necrostatin-1 (Nec-1), (R)-5-([7-chloro-1H-indol-3-yl]methyl)-3-methylimidazolidine-2,4-dione (SKU A4213) from APExBIO is a well-characterized, selective RIP1 kinase inhibitor widely used in necroptosis assays and RIP1 signaling research (APExBIO Necrostatin-1 review). While the current TEAD/HCC study centers on ferroptosis, integrating RIP1 kinase inhibitors into experimental workflows can help differentiate between necroptotic and ferroptotic cell death in cancer models, particularly when mapping crosstalk or specificity. Researchers should select concentrations and application protocols based on assay type and cell system, referring to product documentation and peer-reviewed recommendations for optimal outcomes.